EverPoint Asset Management’s Pacific Biosciences PACB Stock Holding History

EverPoint Asset Management’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-950,000	Closed	-$8.07M	–	490
2016 Q1	$8.07M	Buy	+950,000	New	+$9.34M	0.16%	162
2015 Q4	–	Sell	-800,000	Closed	-$2.93M	–	507
2015 Q3	$2.93M	Sell	800,000 -100,010	-11%	-$489K	0.08%	291
2015 Q2	$5.18M	Buy	+900,010	New	+$5.21M	0.09%	272

Other funds holding PACB

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

RCM

Raging Capital Management Rocky Hill, New Jersey $18.2M AUM 17.75% 1-Year Est. Return

EverPoint Asset Management's PACB Position: Q2 2016 in Review

EverPoint Asset Management sold out of Pacific Biosciences (PACB) in Q2 2016, closing a stake of 950,000 shares — an estimated $8.07M sold.

EverPoint Asset Management first reported a position in PACB in Q2 2015 and held it in 3 quarters. The position peaked at $8.07M in Q1 2016. 141 funds tracked by Wall St. Rank hold PACB as of Q2 2016.

EverPoint Asset Management reported no remaining Pacific Biosciences position as of Q2 2016 after selling out during the quarter.
EverPoint Asset Management sold 950,000 Pacific Biosciences shares in Q2 2016, an estimated $8.07M.
EverPoint Asset Management first reported a position in Pacific Biosciences in Q2 2015 and held it in 3 quarters.
EverPoint Asset Management's Pacific Biosciences position peaked at $8.07M in Q1 2016.
141 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2016.

Based on EverPoint Asset Management's 13F filing for Q2 2016, filed 15 Aug 2016.